Replimune

Yahoo Finance • 25 days ago

Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision

We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Replimune Group, Inc. is among the best biotech stocks to invest in. TheFly reported on April 13 that Jefferies cut its rating on REPL from Buy to Hold and reduce... Full story

Yahoo Finance • 29 days ago

Street sours on Replimune as stock hits all-time low on melanoma drug rejection

[Financial crisis down 3d red arrow economy business graph on money crash market background with bankruptcy decrease bad finance chart diagram or loss investment economic recession sales and low price.] Lemon_tm As shares of Replimune Gro... Full story

Yahoo Finance • 29 days ago

Replimune Group, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Replimune Group, Inc. (NASDAQ: REPL). The investigation focuses on Replimune’s executive officers and whether... Full story

Yahoo Finance • 29 days ago

Replimune shares extend losses, tumble 56% after FDA rejects melanoma drug RP1

[Chemist developing new medicine in laboratory] Luis Alvarez * Replimune shares tumbled 56% in premarket trading on Monday after the FDA on Friday declined [https://seekingalpha.com/news/4574207-replimune-sees-layoffs-fda-snubs-cancer-d... Full story

Yahoo Finance • last month

FDA Review Looms As Replimune Faces Weak Technical Setup

Replimune Group shares are down on Thursday. The company faces an upcoming FDA review decision on Friday, 10 April. Replimmune RP1 Filing Faces Regulatory Hurdles In October 2025, the U.S. Food and Drug Administration (FDA) accepted the... Full story

Yahoo Finance • last month

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a com... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Friday afternoon, with the NYSE Health Care Index falling 1.1% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Lower Friday Afternoon

Health care stocks declined Friday afternoon, with the NYSE Health Care Index decreasing 0.7% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Catalyst Watch: OPEC meeting, FedEx talks freight, inflation reads, and SpaceX IPO buzz

[Wall street and Broadway road sign in New York City] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. SUN... Full story

Yahoo Finance • 2 months ago

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap... Full story

Yahoo Finance • 3 months ago

Replimune Group GAAP EPS of -$0.77 beats by $0.01

* Replimune Group press release [https://seekingalpha.com/pr/20385487-replimune-reports-fiscal-third-quarter-2026-financial-results-and-provides-corporate-update] (REPL [https://seekingalpha.com/symbol/REPL]): Q3 GAAP EPS of -$0.77 beats... Full story

Yahoo Finance • 6 months ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that biomarker data and updated... Full story

Yahoo Finance • 7 months ago

Trending tickers: HSBC, Cleveland-Cliffs, GSI Technology, Beyond Meat and Replimune

Cleveland-Cliffs (CLF) Shares in Cleveland-Cliffs were lower in pre-market trading after closing 21% higher on Monday as the US steelmaker said it would increase efforts to develop its rare earth minerals business, an increasingly strateg... Full story

Yahoo Finance • 7 months ago

Noteworthy Monday Option Activity: UNH, REPL, CELC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 92,988 contracts has been traded thus far today, a contract... Full story

Yahoo Finance • 7 months ago

Replimune soars 108% on BLA resubmission acceptance of melanoma asset

[Percentage Symbol with Slash Transforming into Upward Growth Graph Representing Financial Gains and Market Trends] J Studios * The US FDA has accepted Replimune's (NASDAQ:REPL [https://seekingalpha.com/symbol/REPL]) BLA submission of R... Full story

Yahoo Finance • 7 months ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Admi... Full story

Yahoo Finance • 7 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis... Full story

Yahoo Finance • 7 months ago

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Replimune between November 2... Full story

Yahoo Finance • 8 months ago

Investors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit... Full story

Yahoo Finance • 8 months ago

REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Replimune Group, Inc. Investors to Contact the Firm Regarding Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Replimune between Novem... Full story